CDNA vs HUM: fair value comparison
CareDx, Inc. and Humana Inc. · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CDNA currently sits closer to the top of our discount ranking. CDNA carries the stronger quality grade.
| CDNA | HUM | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $47.85 | $385.54 |
| 12-month range | $13.85–$47.85 | $176.95–$374.50 |
| Sector rank | #107 of 113 Healthcare | #108 of 113 Healthcare |
| Quality grade | A | C |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CDNA fair value analysis · HUM fair value analysis